Funding dependent, we are expecting exciting developments in 2024, lined up for three Phase 2 studies and a goal to publish our ARDS preclinical trial results, once some follow-up lab work is done.
In 2022, we completed an ARDS study and discovered that our drug has multiple pathways to at least five inflammatory markers. We were able to show that our drug, RP-323, can reduce inflammation in the lung at two time points, 24 and 96 hours. (Our drug also reduces inflammation in the brain by more than 70%, by down regulating Aquaporin 3). We raised $700,000 from an Angel Investor to manufacture another batch of study drug, RP-323.
In 2023, feasibility studies remain ongoing. We completed feasibility for Parkinson’s disease and started Parkinson’s preclinical study design. We completed a feasibility study for ARDS Phase 2 human trial and started the study design. We are working on a new discovery that is with our patent attorney, where he is perfecting and writing the application.
AML and HL Phase 2 protocols are final. We are now working to raise the needed funds for these clinical studies, along with the above-mentioned studies in ARDS and Parkinson’s.
